Swissmedic announced its approval on Wednesday making Nuvaxovid the first protein-based vaccine to be licensed in Switzerland. The American biotech firm Novavax had applied for approval on February 14 through Swiss partner Future Health Pharma.
Unlike other Covid-19 vaccine approved in Switzerland – the mRNA vaccines from Pfizer/BioNTech and Moderna and the viral vector vaccine from Johnson & Johnson – Nuvaxovid is a protein-based vaccine. According to Swissmedic, it contains a non-infectious component from the surface of the SaRS-CoV-2 virus which triggers a protective immune response when the body’s immune cells come into contact with it. The vaccine contains an adjuvant to strengthen the immune response.
The vaccine must be administered in two doses three weeks apart. The level of protection offered by Nuvaxovid seven days after the second dose is 90%. It can be stored in a refrigerator for up to nine months.
“We are proud that Switzerland is part of the growing list of countries approving Nuvaxovid and that people in Switzerland will have a protein-based Covid-19 vaccine option,” said Novavax CEO Stanley C. Erck.
Swissmedic’s decision was based on the totality of preclinical, manufacturing and clinical trial data submitted for review. This includes two pivotal phase III clinical trials: PREVENT-19, which enrolled approximately 30,000 participants aged 18 and older in the US and Mexico and was published in the New England Journal of Medicine.
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
This content was published on
Three independent UN experts call on Switzerland and other countries to redouble efforts a year after a ECHR ruling in favour of Climate Elders.
“No US tariff negotiations”: Swiss economics minister
This content was published on
Switzerland has yet to enter formal tariff negotiations with the United States despite making contact with the administration.
Soaring cocoa prices hit Swiss chocolate maker Barry Callebaut
This content was published on
Swiss chocolate maker Barry Callebaut suffered from soaring cocoa prices in the first half of the 2024-2025 financial year.
Switzerland faces income losses from US tariffs, says ETH Zurich
This content was published on
Compared to Germany and France, Switzerland would face “significantly higher losses,” says ETH Zurich’s Centre for Economic Research (KOF).
Christian Oppliger named new head of the Swiss Air Force
This content was published on
Christian Oppliger has been named the new head of the Swiss Air Force, starting on October 1. He succeeds Peter Merz, who will become CEO of Skyguide.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.